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Abstract
  The  survival  rate  of  cancer  patients  has  greatly  in-
creased over the last 20 years. However, to achieve this re-
sult, a considerable price has been paid in terms of the side 
effects associated with the intensive anticancer treatment. 
The most common adverse effect is cardiotoxicity which 
may compromise the clinical effectiveness of chemotherapy, 
affecting the patient’s survival and quality of life indepen-
dently of the oncological prognosis. There are 2 types of 
cardiac toxicities, type I which is more serious and result in 
permanent damage to the myocardium and type II which is 
usually reversible. Chemotherapies varies in their incidence 
of inducing cardiomyopathy, and the onset which may oc-
cur acutely (during or shortly after treatment), sub-acutely 
(within days or weeks after completion of chemotherapy) 
or chronically (weeks to months after drug administration). 
Cardiac events associated with chemotherapy may consist 
of mild blood pressure changes, thrombosis, Electrocardio-
graphic (ECG) changes, arrhythmias, myocarditis, pericar-
ditis, myocardial infarction, cardiomyopathy, cardiac failure 
(left ventricular failure), and congestive heart failure (CHF). 
The risk for such effects depends upon: cumulative dose, rate 
of drug administration, mediastinal radiation, advanced age, 
younger age, female gender, pre-existing heart disease and 
hypertension. Serial measurements of LVEF and fractional 
shortening are the most common indices monitored to assess 
left ventricular systolic function and cardiotoxicity. This can 
be achieved by 2-dimensional, M-mode and color Doppler 
echocardiographic examination; also Cardiac troponins as a 
biological marker for myocardial damage can be used for 
monitoring in patients received anthracyclines. Angiotensin-
converting  enzyme  (ACE)  inhibitors  (ACEIs)  have  been 
shown to slow the progression of left ventricular dysfunction 
in several different clinical settings, including anthracycline-
induced cardiomyopathy. Carvedilol and probably with anti-
oxidants like Probucol and vitamin E benefits also.
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Introduction
     Chemothearpies  are highly effective in treating most   
cancers, their use is limited by the potential for cardiotoxic-
ity. All these drugs have a wide range of adverse effects the 
most serious one is  cardiotoxicity,  these severity of these 
effects are related to the  chemotherapy regimens, patient 
populations and duration. The occurrence of clinical heart 
failure seems to be in the range of 1% to 5%, and asymp-
tomatic decrease in left ventricular function is in the range of 
5% to 20%. Toxicity can occur early (within 1 year) or late 
(particularly among children, where late cardiac abnormali-
ties are detectable in two thirds of surviving patients). 
      Many  trials  address  the  role  of ACE  inhibitors  and 
beta-blockers,  effective  therapies  for  established  LVSD, 
in  preventing  chemotherapy-induced  cardiotoxicity.  In 
this  article  we  discuss  the  types  of  the  cardiomyopa-
thy,  diagnosis,  prognosis,  prevention  and  managements. 
 
Chemotherapy induced cardiomyopathy
  The  survival  rate  of  cancer  patients  has  greatly  in-
creased over the last 20 years. However, to achieve this re-
sult, a considerable price has been paid in terms of the side 
effects associated with the intensive anticancer treatment. 
Cardiotoxicity  may  compromise  the  clinical  effectiveness 
of chemotherapy, affecting the patient’s survival and quality 
of life independently of the oncological prognosis. As a re-
sult of the increasing number of long-term cancer survivors  doi:10.4021/jocmr2009.02.1225
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and of the tendency to use higher doses of cytotoxics and 
combined treatments with synergistic cardiotoxic effects, the 
magnitude of this problem is growing. Accordingly the onset 
of cardiac dysfunction, even if it is asymptomatic, not only 
negatively affects cancer patients’ cardiac outcomes, but also 
seriously limits their therapeutic opportunities. There are 2 
types of cardiac toxicities, type I which is more serious and 
result in permanent damage to the myocardium and type II 
which is usually reversible. Features and risk factors of both 
types  summarised  in  Table  1. Anthracyclines,  even  after 
three decades, continue to play a prominent role in the treat-
ment of a wide variety of both hematologic and solid tumors; 
it is now well established that anthracycline cardiotoxicity 
is a cumulative dose-related effect, suggesting that each ad-
ministration constitutes additive or sequential damage.
  As early as 1967, there were reports of heart failure 
in children treated with doxorubicin for leukemia; from that 
time  concerns  regarding  chemotherapy  starts. Aggressive 
and combination chemotherapy has achieved remission in 
most types of cancers. However, concerns for, or manifesta-
tions of, cardiac adverse events may result in discontinuation 
of or reluctance to use a particular agent at an effective dose.   
Cytostatic antibiotics of the anthracycline class have been 
clearly associated with cardiotoxicity. However, there are a 
number of other chemotherapy agents that cause cardiotoxic-
ity and yet are not well recognized Cardiac events associated 
with chemotherapy vary in incidence and may occur acutely 
(during or shortly after treatment), sub-acutely (within days 
or weeks after completion of chemotherapy) or chronical-
ly (weeks to months after drug administration). They may 
also occur as late squeal, many years after the end of treat-
ment.  Cardiac  events  associated  with  chemotherapy  may 
consist of mild blood pressure changes, thrombosis, Elec-
trocardiographic (ECG) changes, arrhythmias, myocarditis, 
pericarditis, myocardial infarction, cardiomyopathy, cardiac 
failure (left ventricular failure), and congestive heart failure 
(CHF).  The substantial limitations of using only changes in 
LVEF are compromised further by our knowledge that ap-
proximately half of all heart failure occurs in patients who 
maintain a normal LVEF; their overall cardiac outcomes are 
similar to those who exhibit a low LVEF  [1]. 
  Cardiotoxicity may depend on the dose administered 
during each course or on the total cumulative dose, or may 
be completely independent of the dose like Anthracycline-
induced cardiotoxicity which has been recognized for more 
than 20 years. It has been described as 3 distinct types of 
cardiotoxicity. Acute or sub-acute injury is a rare form of 
cardiotoxicity that may occur immediately after a single dose 
or a course of anthracycline therapy, with clinical manifesta-
tions occurring within a week of treatment. These may be 
in the form of transient electrophysiological abnormalities, 
a pericarditis, myocarditis syndrome or acute left ventricular 
failure. The electrophysiological abnormalities may present 
as nonspecific ST and T wave changes, T wave flattening, 
decreased  QRS  voltage  and  prolongation  of  QT  interval. 
Sinus tachycardia is the most common rhythm disturbance. 
ECG changes may be seen in 20 to 30% of the patients [2]. 
Arrhythmias,  including  ventricular,  supraventricular  and 
junctional tachycardia, are seen in 0.5 to 3% of patients with 
an overall incidence of 0.7% [2]. More serious arrhythmias, 
such as atrial flutter or atrial fibrillation, are rare. Sub-acute 
cardiotoxicity has resulted in acute failure of the left ventri-
cle, pericarditis or a fatal pericarditis-myocarditis syndrome 
in some rare cases. The ECG changes or arrhythmias do not 
seem related to chronic cardiomyopathy. 
 Early onset chronic progressive cardiotoxicity: anthra-
cyclines  can  also  induce  early  onset  progressive  chronic 
cardiotoxicity resulting in cardiomyopathy. This is a more 
common and clinically important type of cardiotoxicity [3].
Chronic  anthracycline-induced  cardiomyopathy  usually 
presents within a year of treatment. It may persist or prog-
ress even after discontinuation of anthracyclines therapy, and 
may evolve into a chronic dilated cardiomyopathy in adult 
patients and restrictive cardiomyopathy in pediatric patients 
[4]. Late onset chronic progressive anthracycline cardiotox-
icity causes ventricular dysfunction [5], heart failure and ar-
rhythmias [6] years to decades after chemotherapy has been 
completed. This suggests that patients who have received 
anthracyclines chemotherapy and survived their cancer may 
have undetected increases in morbidity and mortality due to 
cardiotoxicity. There may be a period of time, after comple-
Table 1. Chemotherapy related cardiac dysfunction
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TYPE  I
e.g. Doxorubicin 
TYPE II
e.g. Trastuzumab
Cellular death 
Damage starts with first
administration
Cellular  dysfunction
Biopsy changes No typical biopsy changes
Cumulative dose related Not cumulative dose related
Permanent damage
(Myocyte death)
Predominately reversible
(Myocyte dysfunction)
Risk factors
   Combination chemotherapy
   Prior/concurrent radiotherapy
   Age
   Previous cardiac disease
   Hypertension
Risk factors
   Paclitaxel
   Prior/concurrent anthracycline
   Age
  Previous cardiac disease
  Obesity (BMI > 25kg/sm)Chemotherapy Induced Cardiomyopathy J Clin Med Res  •  2009;1(1):8-12
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tion of treatment, during which patients may experience no 
symptoms of left ventricular dysfunction or arrhythmia and 
cardiac function may appear normal. After the initial acute 
myocardial insult, there is a progressive decrease in ventric-
ular function leading to late onset decompensation. An in-
creased incidence of severe echocardiographic abnormalities 
has been seen with increased duration of follow-up. An 18% 
incidence of reduction in fractional shortening on resting 
echocardiogram was observed 4 to 10 years after completion 
of anthracycline therapy [6]. Cumulative doses of doxorubi-
cin as low as 228 mg/m2 have shown to increase after-load 
or decrease contractility, or both, in 65% of patients with 
leukaemia up to 15 years after treatment with anthracyclines 
[7]. Late onset arrhythmia and sudden death has occurred 
more than 15 years after anthracycline treatment [8]. This 
could mean that more anthracyclines induced cardiotoxic-
ity may appear in the future in patients who are presently 
asymptomatic. Patients may remain in a compensated state 
for many years until stressors such as acute viral infection 
[9] or cardiovascular stressors such as weight lifting, preg-
nancy and surgery [6] could possibly trigger a cardiac event.   
 
Pathogenesis
 The  cause  of  anthracycline-induced cardiotoxicity is 
probably  multi-factorial.  Free  radical–mediated  myocyte 
damage is one of the most thoroughly studied mechanisms 
by which anthracyclines have been proposed to cause car-
diotoxicity  [10].  The  myocardium  is  more  susceptible  to 
free radical damage than other tissues because it has com-
paratively less superoxide dismutase and catalase activity, 
and its major defense against free radical damage, glutathi-
one peroxidase, is suppressed by doxorubicin. The super-
hydroxide free radicals accumulate and cause severe lipid 
peroxidation, leading to extensive destruction of the mito-
chondrial membranes, endoplasmic reticulum and nucleic 
acid.  Circulating  pro-inflammatory  cytokines  have  also 
been  implicated  in  anthracycline  cardiotoxicity.  Doxo-
rubicin  induces  the  release  of  histamine  and  tumour  ne-
crosis  factor-α  from  macrophages  and  interleukin-2  from 
monocytes [11]. These cytokines have functional receptors 
on the myocardium and their release may result in dilated 
cardiomyopathy. Adrenergic dysfunction and down regula-
tion  of  myocardial  histamine  and  β-adrenergic  receptors 
has also been proposed as a cause for an evolving and es-
tablished  anthracycline–induced  ventricular  dysfunction. 
 
Risk factors for cardiotoxicity
  Some of the risk factors relating to early and late (but 
not acute) cardiotoxicity have been reported. These include 
cumulative  dose,  rate  of  drug  administration,  mediastinal 
radiation, advanced age, younger age, female gender, pre-
existing  heart  disease  and  hypertension.  A  multivariate 
analysis of these factors based on histological evidence of 
anthracycline-induced cardiac damage concluded that higher 
rates of administration and previous cardiac irradiation were 
independent risk factors. At a cumulative total dose of < 400 
mg/m2 body surface area, the incidence of CHF was found 
to be 0.14%. This increased to 7% at a dose of 550 mg/m2 
and to 18% at a dose of 700 mg/m2 [4].  There is a formula 
to calculate the cardiac toxicity as follow Y= (X)2/a, Y is the 
likelihood of developing congestive heart failure, X equals 
to number of cycles of anthracycline-containg regimen ad-
ministered, a equals to correction constant determined by cy-
cle dose and the duration between the cycles,  so if a patient 
receives 9 cycle of anthracycline in a dose of 50 mg/m2 every 
21 days, so it will be Y= 81/16 X100,  the Y will be equal to 
5%, this is the risk of developing congestive heart failure [4].     
  Serial and post-therapy cardiac monitoring is neces-
sary to reduce morbidity due to anthracycline-induced car-
diotoxicity. Patients should be monitored for clinical signs 
of cardiomyopathy by physical examination, chest x-rays, 
ECG,  echocardiogram,  endomyocardial  biopsy  if  feasible 
and radionuclide angiography before initiation of treatment 
and at periodic intervals during therapy. Physical examina-
tion alone may miss over 50% of cases of early and revers-
ible chemotherapy-induced CHF [12]. Acute ECG changes 
and arrhythmias following doxorubicin therapy occur in 0 to 
14% of patients. Serial measurements of LVEF and fractional 
shortening are the most common indices monitored to assess 
left ventricular systolic function and cardiotoxicity. This can 
be achieved by 2-dimensional, M-mode and color Doppler 
echocardiographic examination. Baseline LVEF estimation 
is recommended before the start of doxorubicin therapy. If 
LVEF is ≤ 30%, starting chemotherapy is not recommended. 
Patients with LVEF ≥ 30% but <50% can receive doxorubi-
cin, but measurements should be repeated before each dose. 
For patients with baseline LVEF ≥ 50%, evaluations should 
be repeated after a cumulative dose of 250 to 300 mg/m2 
and thereafter at 450 mg/m2 if they have no risk factors. If 
patients have known cardiovascular disease, prior radiation 
treatment to the chest, abnormal ECG changes or concomi-
tant cardiotoxic chemotherapy, LVEF measurement should 
be repeated at 400 mg/m2 instead of 450 mg/m2. It should 
be monitored with each dose thereafter. Doxorubicin therapy 
should be stopped if there is a ≥ 10% absolute drop in the 
ejection fraction associated with a decrease in LVEF to ≤ 
50% in patients with baseline LVEF ≥ 50%, and to ≤ 30% in 
patients with baseline LVEF < 50% but > 30%  [13].   
  Biomarkers such as B-type natriuretic peptide and tro-
ponins (I and T) are increasingly being used to stratify pa-
tients into higher and lower risk categories. This process is 
well established in the cardiology literature and recently has 
been reported in oncology patients. In fact, an elevated tropo-
nin during chemotherapy seems to correlate with increased 
risk for the development of cardiac toxicity [14]. Cardiac 
troponins as a biological marker for myocardial damage can 
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be used for monitoring in patients received anthracyclines. 
troponin I (TnI) soon after high-dose chemotherapy (HDC) 
is a strong predictor of left ventricular dysfunction and poor 
cardiac outcome, particularly in patients showing a persis-
tent TnI increase [15]. 
  Some cardio-protective agents is used which associated 
with a decrease in cardiotoxicity and facilitates the use of 
higher cumulative doses of anthracyclines but it is beyond 
our  article. Also  Cardiotoxicity  of  anthracyclines  can  be 
minimized by using analogues that may be less cardiotoxic. 
Compounds such as epirubicin and idarubicin exhibited de-
creased cardiotoxicity in preclinical trials.
 The use of anti-oxidant agents or iron chelators finds 
their  way  in  the  prevention  for  cardiac  toxicities.  Probu-
col, vitamin E (as anti-oxidants) and carvedilol have shown 
promise in animal studies. 
  Angiotensin-converting  enzyme  (ACE)  inhibitors 
(ACEIs) have been shown to slow the progression of left 
ventricular dysfunction in several different clinical settings, 
including anthracycline-induced cardiomyopathy [16]. Fur-
thermore, data referring to experimental models suggest that 
the cardiac renin-angiotensin system (RAS) plays an impor-
tant role in the development of anthracycline-induced car-
diomyopathy and that treatment with ACEIs protects against 
chemotherapy-induced  cardiotoxicity.  In  a  recent  study 
showed that  [17] early treatment with enalapril in patients 
with evidence of myocardial cell injury (TnI increase) af-
ter HDC seems to prevent the development of cardiotoxic-
ity and the occurrence of associated adverse clinical events. 
The benefits of and clinical indications for ACEIs have been 
clearly defined in many cardiovascular conditions such as 
chronic heart failure, asymptomatic left ventricular dysfunc-
tion, acute myocardial infarction, and hypertension and in 
patients at increased risk of cardiovascular events. In car-
diomyopathy, because of anthracycline induced cardiotoxic-
ity, the use of enalapril has been proved to be beneficial in 
prolonging survival and in preventing further deterioration 
of cardiac function.
    At the end, frequent monitoring and follow up for patients 
took anthracyclines with troponins and echocardiograms with 
early  administration  of  carvedilol,  enalapril  and  probably 
with anti-oxidants like Probucol and vitamin E will benefit. 
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